Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3POT6)

Drug Name

ATL1102 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ITGA4 messenger RNA (ITGA4 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-0668	DMVBFJP	Discovery agent	N.A.	Investigative	[3]
ISIS 24477	DMCNBIL	Discovery agent	N.A.	Investigative	[4]
ISIS 24448	DMLHQ2J	Discovery agent	N.A.	Investigative	[4]
ISIS 24453	DM45WUZ	Discovery agent	N.A.	Investigative	[4]
ISIS 24475	DMBKZOQ	Discovery agent	N.A.	Investigative	[4]
ISIS 24454	DMDE3J1	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
2	CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.Neurology.2014 Nov 11;83(20):1780-8.
3	Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
4	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.